Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).

Alan L Ho,Nathan R Foster, Alex J Zoroufy,Jordan D Campbell,Francis Worden,Katharine Price,Douglas Adkins,Daniel W Bowles,Hyunseok Kang,Barbara Burtness,Eric Sherman, Roscoe Morton,Luc G T Morris,Zaineb Nadeem,Nora Katabi,Pamela Munster,Gary K Schwartz

Journal of clinical oncology : official journal of the American Society of Clinical Oncology（2022）

引用 14|浏览28

暂无评分

摘要

Enzalutamide demonstrated limited activity in AR+ SGC, failing to meet protocol-defined success in part because of a lack of response durability. Strategies to enhance the efficacy of antiandrogen therapy are needed.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要